SAN FRANCISCO--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that on December 6th it presented positive data from a Phase II study of darinaparsin (ZinaparTM) for the treatment of advanced lymphomas at the 50th American Society of Hematology (ASH) Annual Meeting held in San Francisco, CA.
